Published in Science on September 30, 1994
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet (2009) 8.44
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet (2001) 3.75
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Myriad Genetics: In the eye of the policy storm. Genet Med (2010) 3.30
Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28
How many more breast cancer predisposition genes are there? Breast Cancer Res (1999) 3.10
The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A (1998) 2.85
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet (1997) 2.77
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53
Genetic susceptibility to breast cancer. Mol Oncol (2010) 2.52
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet (1995) 2.42
Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol (1997) 2.40
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet (1997) 2.33
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet (1997) 2.31
Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet (1997) 2.28
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol (2002) 2.14
Why do women attend familial breast cancer clinics? J Med Genet (2000) 2.13
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res (2009) 2.01
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A (1998) 1.97
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet (1995) 1.85
Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet (1998) 1.75
Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet (1996) 1.75
Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc Natl Acad Sci U S A (1995) 1.73
Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A (1996) 1.70
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 1.68
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet (1997) 1.60
Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet (2000) 1.58
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
The role of prophylactic surgery in cancer prevention. World J Surg (2007) 1.51
Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51
A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet (1997) 1.46
Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics (2003) 1.46
Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A (1995) 1.44
Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. Hered Cancer Clin Pract (2015) 1.40
Outcomes of multimodality breast screening for women at increased risk of familial breast cancer. World J Surg (2010) 1.38
Gene patenting--the Supreme Court finally speaks. N Engl J Med (2013) 1.38
High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol (2001) 1.36
Evaluation of record linkage between a large healthcare provider and the Utah Population Database. J Am Med Inform Assoc (2011) 1.35
Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res (2009) 1.32
Genetic mapping of a naturally occurring hereditary renal cancer syndrome in dogs. Proc Natl Acad Sci U S A (2000) 1.31
Direct isolation of human BRCA2 gene by transformation-associated recombination in yeast. Proc Natl Acad Sci U S A (1997) 1.30
Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A (2011) 1.28
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA (2015) 1.26
Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer (2004) 1.25
Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet (1996) 1.24
Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet (2006) 1.24
Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol (1995) 1.21
Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ (1996) 1.20
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A (1998) 1.19
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res (2005) 1.19
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma (2008) 1.18
Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet (1997) 1.16
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer (1998) 1.16
Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup. J Med Genet (1997) 1.15
Genetics of breast cancer: a topic in evolution. Ann Oncol (2015) 1.15
Journeys into the genome of cancer cells. EMBO Mol Med (2013) 1.15
The complex genetic landscape of familial breast cancer. Hum Genet (2013) 1.14
A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer. CMAJ (1996) 1.12
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers (2009) 1.09
Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol (2011) 1.08
The European opposition against the BRCA gene patents. Fam Cancer (2006) 1.08
Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup. J Med Genet (1998) 1.08
Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil. Genet Mol Biol (2009) 1.08
Segregation analysis of phenotypic components of learning disabilities. I. Nonword memory and digit span. Am J Hum Genet (2000) 1.08
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
Germline BRCA2 mutations in men with breast cancer. Br J Cancer (1997) 1.07
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet (1999) 1.06
Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. Fam Cancer (2001) 1.05
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer (2011) 1.05
Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol (1997) 1.04
Linkage analysis of adult height in a large pedigree from a Dutch genetically isolated population. Hum Genet (2009) 1.04
Screening for 185delAG in the Ashkenazim. Am J Hum Genet (1997) 1.04
Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci (2012) 1.04
Genetic epidemiology of glioma. Br J Cancer (2001) 1.03
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res (2002) 1.02
Structure-Function Of The Tumor Suppressor BRCA1. Comput Struct Biotechnol J (2012) 1.02
BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS One (2008) 1.01
The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol (2003) 1.01
The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl (2012) 1.00
Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet (2008) 0.99
A mechanosensory system controls cell shape changes during mitosis. Cell Cycle (2007) 0.99
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol (2015) 0.99
Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet (2008) 0.99
A large multisite cancer family is linked to BRCA2. J Med Genet (1995) 0.98
Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol (2009) 0.98
Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med (2014) 0.97
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Identification of the breast cancer susceptibility gene BRCA2. Nature (1996) 17.14
Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 14.41
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1993) 11.01
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science (1987) 5.11
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
Health of the public. The academic response. Health of the Public Mission Statement Working Group. JAMA (1992) 2.95
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med (1998) 2.80
Pathogen-specific loss of host resistance in mice lacking the IFN-gamma-inducible gene IGTP. Proc Natl Acad Sci U S A (2000) 2.80
A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res (2000) 2.79
Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet (1997) 2.77
Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A (1999) 2.71
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40
Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol (1997) 2.35
Undetected eye disease in a primary care clinic population. Arch Intern Med (1994) 2.32
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Can health visitors prevent fractures in elderly people? BMJ (1992) 2.25
Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care (2000) 2.23
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood (1999) 2.22
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Inter-neonatal intensive care unit variation in discharge timing: influence of apnea and feeding management. Pediatrics (2001) 1.98
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet (2005) 1.94
A G protein gamma subunit-like domain shared between RGS11 and other RGS proteins specifies binding to Gbeta5 subunits. Proc Natl Acad Sci U S A (1998) 1.94
Genetics of coeliac disease. QJM (1996) 1.90
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (2001) 1.87
Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg (2001) 1.87
Quantitative brain magnetic resonance imaging in girls with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (2001) 1.84
Prenatal health behaviors and psychosocial risk factors in pregnant women of Mexican origin: the role of acculturation. Am J Public Health (1997) 1.83
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med (2001) 1.80
Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res (1998) 1.73
Genetic analysis of NF1: identification of close flanking markers on chromosome 17. Genomics (1987) 1.73
Advances in the molecular genetic analysis of the flax-flax rust interaction. Annu Rev Phytopathol (1997) 1.72
Experimental Borrelia burgdorferi infection in inbred mouse strains: antibody response and association of H-2 genes with resistance and susceptibility to development of arthritis. Eur J Immunol (1991) 1.71
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 1.68
Filters on the pathway to mental health care, II. Sociodemographic factors. Psychol Med (1995) 1.66
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol (1996) 1.65
DNA sequence variation within maize and melon: observations from polymerase chain reaction amplification and direct sequencing. Genetics (1990) 1.64
Genetic dissection of honeybee (Apis mellifera L.) foraging behavior. J Hered (2001) 1.64
Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis. Genes Immun (2006) 1.64
Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ (1999) 1.63
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
The localization of glycollate-pathway enzymes in Euglena. Biochem J (1975) 1.62
In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med (1997) 1.61
Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol (1995) 1.61
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets (2010) 1.60
Role of TCR zeta chain in T cell development and selection. Science (1994) 1.59
Oxidative phosphorylation during glycollate metabolism in mitochondria from phototrophic Euglena gracilis. Biochem J (1975) 1.59
Taurocholate transport by rat liver sinusoidal membrane vesicles: evidence of sodium cotransport. Hepatology (1982) 1.57
Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol (1995) 1.57
A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation. Biomaterials (2005) 1.57
Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity (1997) 1.56
Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med (1993) 1.53
Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Int J Radiat Oncol Biol Phys (2001) 1.53
Rat liver canalicular membrane vesicles. Isolation and topological characterization. J Biol Chem (1983) 1.51
Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol (1999) 1.50
Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci U S A (1999) 1.46
Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke (2001) 1.46
GTPase activating specificity of RGS12 and binding specificity of an alternatively spliced PDZ (PSD-95/Dlg/ZO-1) domain. J Biol Chem (1998) 1.45
Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest (1993) 1.45